Novartis (NVS)
(Delayed Data from NYSE)
$116.37 USD
+0.43 (0.37%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $116.39 +0.02 (0.02%) 6:24 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Cash flow Statements
Fiscal Year End for Novartis AG falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 8,572.00 | 6,955.00 | 24,018.00 | 8,071.00 | 7,147.00 |
Depreciation/Amortization & Depletion | 8,383.00 | 0.00 | 6,075.00 | 6,129.00 | 5,788.00 |
Net Change from Assets/Liabilities | -369.00 | -1,003.00 | 241.00 | -291.00 | 199.00 |
Net Cash from Discontinued Operations | 238.00 | 0.00 | 0.00 | 0.00 | 78.00 |
Other Operating Activities | -2,366.00 | 8,284.00 | -15,263.00 | -259.00 | 413.00 |
Net Cash From Operating Activities | 14,458.00 | 14,236.00 | 15,071.00 | 13,650.00 | 13,625.00 |
Property & Equipment | -823.00 | -1,031.00 | -1,138.00 | -1,187.00 | -522.00 |
Acquisition/ Disposition of Subsidiaries | -4,681.00 | -903.00 | 20,102.00 | -10,091.00 | -4,919.00 |
Investments | 10,838.00 | 4,674.00 | -13,854.00 | -915.00 | 3,177.00 |
Other Investing Activities | 262.00 | -1,272.00 | -902.00 | -989.00 | 38.00 |
Net Cash from Investing Activities | 5,596.00 | 1,468.00 | 4,208.00 | -13,182.00 | -2,226.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -8,566.00 | -10,552.00 | -3,057.00 | -2,094.00 | -5,533.00 |
Issuance (Repayment) of Debt | -2,223.00 | -2,559.00 | -2,146.00 | 5,123.00 | -3,102.00 |
Increase (Decrease) Short-Term Debt | 288.00 | 0.00 | -3,840.00 | 1,949.00 | -1,855.00 |
Payment of Dividends & Other Distributions | -7,255.00 | -7,506.00 | -7,368.00 | -6,987.00 | -6,645.00 |
Other Financing Activities | 3,478.00 | 55.00 | 147.00 | -199.00 | 3,508.00 |
Net Cash from Financing Activities | -14,278.00 | -20,562.00 | -16,264.00 | -2,208.00 | -13,627.00 |
Effect of Exchange Rate Changes | 100.00 | -32.00 | -266.00 | 286.00 | 69.00 |
Net Change In Cash & Equivalents | 5,876.00 | -4,890.00 | 2,749.00 | -1,454.00 | -2,159.00 |
Cash at Beginning of Period | 7,517.00 | 12,407.00 | 9,658.00 | 11,112.00 | 13,271.00 |
Cash at End of Period | 13,393.00 | 7,517.00 | 12,407.00 | 9,658.00 | 11,112.00 |
Diluted Net EPS | 7.10 | 3.17 | 10.63 | 3.52 | 5.06 |
Fiscal Year End for Novartis AG falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 5,934.00 | 2,688.00 | 8,572.00 | 5,934.00 | 4,611.00 |
Depreciation/Amortization & Depletion | 0.00 | 1,342.00 | 8,383.00 | 6,758.00 | 3,896.00 |
Net Change from Assets/Liabilities | -1,751.00 | -2,565.00 | -369.00 | -1,679.00 | -1,666.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 238.00 | 238.00 | 0.00 |
Other Operating Activities | 2,957.00 | 800.00 | -2,366.00 | 660.00 | -308.00 |
Net Cash From Operating Activities | 7,140.00 | 2,265.00 | 14,458.00 | 11,911.00 | 6,533.00 |
Property & Equipment | -449.00 | -226.00 | -823.00 | -581.00 | -499.00 |
Acquisition/ Disposition of Subsidiaries | -3,594.00 | -263.00 | -4,681.00 | -3,935.00 | -123.00 |
Investments | 1,314.00 | 519.00 | 10,838.00 | 11,235.00 | 10,985.00 |
Other Investing Activities | -1,377.00 | -929.00 | 262.00 | 637.00 | -795.00 |
Net Cash from Investing Activities | -4,106.00 | -899.00 | 5,596.00 | 7,356.00 | 9,568.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -2,690.00 | -1,099.00 | -8,566.00 | -7,310.00 | -5,684.00 |
Issuance (Repayment) of Debt | 323.00 | 0.00 | -2,223.00 | -2,223.00 | 6.00 |
Increase (Decrease) Short-Term Debt | 1,663.00 | 1,153.00 | 288.00 | -322.00 | 161.00 |
Payment of Dividends & Other Distributions | -7,624.00 | -5,207.00 | -7,255.00 | -7,255.00 | -7,255.00 |
Other Financing Activities | -36.00 | -11.00 | 3,478.00 | 3,439.00 | -67.00 |
Net Cash from Financing Activities | -8,364.00 | -5,164.00 | -14,278.00 | -13,671.00 | -12,839.00 |
Effect of Exchange Rate Changes | -160.00 | -126.00 | 100.00 | -708.00 | 106.00 |
Net Change In Cash & Equivalents | -5,490.00 | -3,924.00 | 5,876.00 | 4,888.00 | 3,368.00 |
Cash at Beginning of Period | 13,393.00 | 13,393.00 | 7,517.00 | 7,517.00 | 7,517.00 |
Cash at End of Period | 7,903.00 | 9,469.00 | 13,393.00 | 12,405.00 | 10,885.00 |
Diluted Net EPS | 1.59 | 1.31 | 4.06 | 0.85 | 1.11 |